RCE Takes the Stage at the 2023 American College of Cardiology with Exciting Late Breaking Clinical Trial Results

New Orleans, LA (March 6, 2023) - RCE Technologies, Inc's groundbreaking study titled "A Novel Breakthrough In Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction" was presented at the American College of Cardiology - Late Breaking Clinical Trials on March 6, 2023. The presentation was delivered center stage by Dr. Partho Sengupta, Henry Rutgers Professor of Cardiology and Division Chief of Cardiology at the Rutgers Robert Wood Johnson Medical Center.

The study, which has also been published in the prestigious European Society of Cardiology, focuses on the development of a wrist-worn transdermal troponin-I-sensor for the assessment of acute myocardial infarction. The sensor enables real-time detection of troponin-I levels, a key biomarker of heart damage, through a non-invasive modality that does not require any blood sampling.

"This is a major breakthrough, and posits the potential for improvement in the diagnosis and management of heart attacks," said Atandra Burman, Founder & CEO, RCE. "Time is Muscle. With this wrist-worn sensor, we can provide real-time monitoring of heart muscle injury that can empower clinicians in a much needed timely intervention in patients with an impending heart attack."

For more information, refer to ACC press release, as well as Dr. Sengupta’s comments on the late breaking clinical trial presentation with the European Society of Cardiology.

About RCE.ai:RCE.ai, an innovative artificial intelligence (AI) based medical technology company launched in Carlsbad, Calif., in 2018, is dedicated to early heart attack detection. The company has revolutionized the monitoring of cardiac injury by introducing Infrasensor™, a non-invasive infrared-based wearable device. RCE’s proprietary transdermal approach, enhanced with deep learning techniques, analyzes and associates unique optical signatures with cardiac conditions in real-time. This AI-coupled transdermal approach enables the potential application of RCE’s technology in various emergency care settings and remote monitoring applications. Presently, RCE is engaged in clinical studies to optimize the Infrasensor for clinical use. Through ongoing clinical studies, the company hopes to soon secure FDA approval for its technology, opening the door to making it available for sale in the United States. 

For more information, please visit https://rce.ai/contact, follow us on LinkedIn or X (formerly Twitter), or contact RCE Investor Relations at ir@rce.ai